High Antibody Titer against Apical Membrane Antigen-1 Is Required to Protect against Malaria in the Aotus Model

Sheetij Dutta1*, JoAnn S. Sullivan2, Katharine K. Grady2, J. David Haynes4, Jack Komisar4, Adrian H. Batchelor1, Lorraine Soisson3, Carter L. Diggs3, D. Gray Heppner4, David E. Lanar4, William E. Collins2, John W. Barnwell2*

1 Department of Epitope Mapping, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America, 2 Malaria Branch, Division of Parasitic Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America, 3 Malaria Vaccine Development Program, United States Agency for International Development, Washington, D. C., United States of America, 4 Division of Malaria Vaccine Development, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America

Abstract

A Plasmodium falciparum 3D7 strain Apical Membrane Antigen-1 (AMA1) vaccine, formulated with AS02a adjuvant, slowed parasite growth in a recent Phase 1/2a trial, however sterile protection was not observed. We tested this AS02a and a Montanide ISA720 (ISA) formulation of 3D7 AMA1 in Aotus monkeys. The 3D7 parasite does not invade Aotus erythrocytes, hence two heterologous strains, FCH/4 and FVO, were used for challenge, FCH/4 AMA1 being more homologous to 3D7 than FVO AMA1. Following three vaccinations, the monkeys were challenged with 50,000 FCH/4 or 10,000 FVO parasites. Three of the six animals in the AMA1+ISA group were protected against FCH/4 challenge. One monkey did not become parasitemic, another showed only a short period of low level parasitemia that self-cured, and a third animal showed a delay before exhibiting its parasiticemic phase. This is the first protection shown in primates with a recombinant P. falciparum AMA1 without formulation in Freund's complete adjuvant. No animals in the AMA1+AS02a group were protected, but this group exhibited a trend towards reduced growth rate. A second group of monkeys vaccinated with AMA1+ISA vaccine was not protected against FVO challenge, suggesting strain-specificity of AMA1-based protection. Protection against FCH/4 strain correlated with the quantity of induced antibodies, as the protected animals were the only ones to have in vitro parasite growth inhibitory activity of >70% at 1:10 serum dilution; immuno-fluorescence titers >8,000; ELISA titers against full-length AMA1 >300,000 and ELISA titer against AMA1 domains1+2 >100,000. A negative correlation between log ELISA titer and day 11 cumulative parasitemia (Spearman rank r = -0.780, p value = 0.0001), further confirmed the relationship between antibody titer and protection. High titers of cross-strain inhibitory antibodies against AMA1 are therefore critical to confer solid protection, and the Aotus model can be used to down-select future AMA1 formulations, prior to advanced human trials.

Citation: Dutta S, Sullivan JS, Grady KK, Haynes JD, Komisar J, et al. (2009) High Antibody Titer against Apical Membrane Antigen-1 Is Required to Protect against Malaria in the Aotus Model. PLoS ONE 4(12): e8138. doi:10.1371/journal.pone.0008138

Editor: Aric Gregson, University of California Los Angeles, United States of America

Received August 7, 2009; Accepted October 23, 2009; Published December 3, 2009

This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration which stipulates that, once placed in the public domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose.

Funding: Funding for this work was provided by U.S. Agency for International Development (USAID) Malaria Vaccine Development Program. Two of the authors on the paper, CLD and LS, are USAID representatives and were involved in the planning phase of this study.

Competing Interests: SD and DEL hold patents on the 3D7 AMA1 vaccine product, however these authors have no financial, personal, or professional interests that influenced the findings of this paper or interfered with the objective assessment of the results in the manuscript. This patent does not alter the adherence of all authors to the PLoS ONE policies on sharing data and materials. Persons responsible for vaccination and reading blood smears, serological testing, specimen collection, provision of health care, and the statistical analysis of the data did not know the experimental group to which the animals were assigned. GlaxoSmithKline Biologicals provided AS02 Adjuvant System used in the research but did not play an analytical role during the study.

* E-mail: sheetij.dutta@us.army.mil (SD); wzbi@cdc.gov (JWB)

Introduction

A vaccine based on a recombinant circumsporozoite protein, RTS,S was shown in a recent phase 2 clinical trial in 5–17 month old children to have 53% vaccine efficacy against P. falciparum malaria clinical episodes. [1]. One strategy to build on the success of this vaccine is to combine it with other antigens [2]. P. falciparum Apical Membrane Antigen-1 (AMA1) is one such promising malaria vaccine candidate [3]. AMA1 is located within the micronemes of Plasmodium merozoites present within blood stage schizonts. At the time of schizont rupture the AMA1 protein gets translocated to the merozoite surface [4], where it plays a vital role in the erythrocyte invasion process [5]. Antibodies against AMA1 are potent inhibitors of merozoite invasion [6]. AMA1 is also present on the surface of sporozoites and AMA1 antibodies inhibit sporozoite invasion into hepatocytes [7].

In the first non human primate vaccine trial reported for AMA1, three rhesus monkeys received 2 doses of an affinity purified native P. knowlesi AMA1 protein vaccine adjuvanted with saponin [8]. Following challenge all three control monkeys required radical drug cure due to acute parasitemia. Two of 3 AMA1 immunized monkeys had parasitemia profiles similar to that of the controls, but one monkey showed a brief delay in patency followed by a self-limiting infection. Upon re-challenge, all 3 immunized animals showed near sterile protection. In a repeat experiment, 3 monkeys received 3 doses of the AMA1 vaccine. As in the first experiment, only 1 out of the 3 monkeys showed a degree of protection. Hence, vaccine efficacy as measured by
reduced parasite burden was 33% and as measured by sterile protection was 0%. Notably serum from the protected monkeys had the highest pre-challenge parasite invasion inhibitory activity against *P. knowlesi* merozoites [8].

A subsequent immunization trial used recombinant *P. fragile* AMA1 in squirrel monkeys [9]. Five *Saimiri* (squirrel) monkeys received 3 doses of a baculovirus-produced recombinant *P. fragile* AMA1 protein vaccine adjuvanted with Montanide ISA720. Following challenge with *P. fragile* blood stage parasites, all 4 control monkeys required drug treatment for high parasitemia. Four out of the 5 AMA1 vaccinated animals showed suppressed parasitemia profiles compared to the controls. The efficacy of this AMA1 vaccine as measured by reduced parasite burden was 80% and as measured by sterile protection was 0%. Serum from the one non-protected animal had the lowest IFA titer while the two best protected animals had the highest titer in the trial [9].

Another trial used *P. cynomolgy* as a challenge parasite in macaque monkeys [10]. Five rhesus monkeys were vaccinated with 3 doses of yeast recombinant *P. vivax* AMA1 adjuvanted with SBAS2 (AS02a). These monkeys were then challenged with the heterologous, yet closely related simian malaria parasite *P. cynomolgy*. However, the course of infection of the AMA1 immunized animals was not different from the control group [10].

Recombinant AMA1 of the *P. chabaudi* rodent malaria parasite also protected vaccinated mice against lethal challenge with a homologous strain of *P. chabaudi*, but no protection was observed against a heterologous strain [11]. As above in primate models, the vaccine efficacy in the rodent models correlated with antibody titers [12] and protection was also conferred upon passive transfer of IgG. Antibodies against conformational epitopes were critical for this protective response [11]. Thus, AMA1 based protection appears to correlate best with antibody levels against conformational epitopes that are strain specific.

More recently and of greater relevance, *Aotus* monkeys were vaccinated with a recombinant *P. falciparum* FVO strain AMA1 protein adjuvanted with Freund's complete/incomplete adjuvant [13]. Following challenge with the homologous FVO strain of *P. falciparum*, 9 of 9 control animals developed high parasitemia and required drug treatment within 15 days of challenge. Of the 6 AMA1 vaccinated animals, 3 showed strong indications of protection (2 were subpatent and 1 had delayed patency). The remaining 3 monkeys developed rapidly rising parasitemia and required treatment for either high parasitemia or anemia. Efficacy as measured by reduced parasite burden was 3/6 (50%) and as measured by sterile protection was 2/6 (33%) [13]. Although, the two monkeys that showed sterile immunity had high ELISA titers, a third monkey with comparable ELISA titer was not protected in the study.

Based on the promising preclinical evidence, Walter Reed Army Institute of Research has developed a 3D7 AMA1 vaccine [2]. This vaccine is under advanced stages of clinical evaluation for efficacy in humans [14,15]. A recent study showed that while the AS01B and AS02A adjuvanted vaccine did not induce protection in humans upon challenge, both had a slight effect on the growth rate of the homologous strain parasite in the blood as observed by quantitative PCR [16]. We present here results from an immunogenicity and efficacy trial with the 3D7 AMA1 vaccine in an *Aotus nancymae* monkey model, conducted at the Centers for Disease Control (Atlanta GA). Two human-use adjuvants, Montanide ISA720 and AS02a were used in the trial. Since the 3D7 strain of *P. falciparum* does not invade Aotus RBC’s [17], two heterologous parasite strains, FCH/4 and FVO, were used for the challenge [18,19]. The former strain being much more homologous to 3D7 than the latter strain.

### Materials and Methods

#### Ethics Statement

This study was approved by the CDC Institutional Animal Care and Use Committee. Animals were housed at a CDC primate facility fully accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC). Aotus monkeys were pair housed, under space recommendations for lab animals set forth by the Care and Use of Laboratory Animals, NIH. Monkeys were fed a diet that was shown to provide adequate nutrition and calories in captive *Aotus* used in malaria research. Animals were weighed at weekly intervals and treated for veterinary problems as they arose by an attending veterinarian. All observations were recorded and entered into a computer database. Blood collections of no more than 5% of a monkey's total blood volume were made by venipuncture and taken biweekly. Persons responsible for handling the monkeys and reading smears for parasitemia did not know the group to which the animal was assigned. All vaccine formulations were free of endotoxin and only human-use adjuvants were used in the study. Monkeys that developed high-density parasitemia (>200,000 parasites/µL of blood) or anemia (hematocrit below 20%) were cured with drugs and treated by iron supplementation and transfusion of whole blood.

#### Animals and Parasites

Following an initial quarantine period monkeys with intact spleens and no history of *Plasmodium* infection were selected for the study. Monkeys were in good health, free of tuberculosis and weighed between 700–1000 g at the start of the study. Thirty animals were stratified into groups of six animals according to weight and sex. Groups were then assigned randomly to the vaccine and control groups. Challenge infection was conducted using two *Aotus* monkey adapted *P. falciparum* strains. The FCH/4 strain was isolated in the Philippines and produces a moderately virulent infection in spleen intact *Aotus nancymae* monkeys with ~50% of monkeys requiring antimalarial treatment following an acute rapidly rising parasitemia. The other ~50% of animals resolve the parasitemia before reaching 200,000 parasites per µL of blood [18]. The Vietnam Oak Knoll (FVO) strain was isolated from a soldier returning from Vietnam and produces a highly virulent infection with >90% of spleen intact *Aotus nancymae* requiring antimalarial treatment [19].

#### Vaccine

The recombinant 3D7 AMA1 vaccine comprising amino acid number 83–531 was expressed in *E. coli* [20]. The 3D7 AMA1 protein used in this trial was produced under GMP conditions, at the WRAIR bioproduction facility. The process used for manufacturing the antigen was essentially as described in Dutta *et al.* 2001 [20], with one exception, the host *E. coli* strain used for protein expression was Tuner(TM) and not Origami(TM) (Invitrogen, Carlsbad CA). The vaccine met the purity criteria for human-use injectables. Residual endotoxin content of the vaccine was 0.004 EU/mg protein by gel clot assay and purity of the protein was ~95% by SDS-PAGE. The protein solution was transported from WRAIR, Silver Spring MD to CDC Atlanta GA, on dry-ice. Figure 1 shows the high level purity of the vaccine protein by SDS-PAGE under non-reducing and reducing conditions, and evidence of correct folding is shown by positive reactivity of the non-reduced protein to a conformation dependent monoclonal antibody 4G2(d)1[21].
Vaccination
Recombinant 3D7 AMA-1 protein was formulated with either Montanide ISA720 (ISA) (Seppic Inc, Paris) or AS02A (GlaxoSmithKline Biologicals, Rixensart, Belgium) Adjuvant System. For ISA720 formulation the antigen in PBS was mixed with the adjuvant in the ratio of 30:70 v/v and vortexed for 10 min to form a thick emulsion. For the AS02A formulation, the lyophilized adjuvant in the ratio of 30:70 v/v and vortexed for 10 min to form a thick emulsion. For ISA720 formulation the antigen in PBS was mixed with the adjuvant in the ratio of 30:70 v/v and vortexed for 10 min to form a thick emulsion. For the AS02A formulation, the lyophilized adjuvant was directly suspended in 0.5 ml of the adjuvant. The control vaccine consisted of PBS formulated with ISA720. Three doses of the vaccine, each containing 40 μg of AMA1 were administered intra-muscular on days 0, 28 and day 84, 0.25 ml vaccine on each thigh. Immunization sites were monitored daily for adverse local reaction and the weight of the animals was recorded at 4 wk interval during the study. Animals were bled for the preparation of serum, complete blood counts and on defined occasions for clinical laboratory values, every two weeks beginning 2 weeks before the first immunization and continuing until the study was completed.

Challenge and Determination of Parasitemia
Three groups of six monkeys were challenged with FCH/4 strain parasites; the groups designated as PBS+ISA_FCH/4, AMA+ISA_FCH/4 and AMA+AS02A_FCH/4. Two other groups were challenged with FVO strain parasites; these were designated as PBS+ISA_FVO and AMA+ISA_FVO. Ring-stage parasitized erythrocytes from a donor monkey were diluted in sterile RPMI 1640 tissue culture medium. On day 112 of the study 50,000 and 10,000 ring stage parasites of the FCH/4 and FVO strain, respectively, were administered intravenously into the monkeys via injection into the femoral vein. Beginning 3 days after the intravenous challenge, Giemsa-stained blood smears were made to establish the number of parasites per μL blood by the quantitative thick film or by thin film, when parasite counts exceeded ~80,000/μL [19]. Daily blood smears were prepared and evaluated for 56 days after the FVO and FCH/4 challenge. Monkeys that developed high-density parasitemia (>200,000 parasites/μL of blood) were treated with mefloquine (Roche Laboratories, Nutley, N.J.) and quinine (Marion Merrel Dow, Inc., Kansas City, Kans.). Animals that developed anemia were cured with drugs and treated by iron supplementation and transfusion of whole blood if the hematocrit fell below 20%. Iron supplementation is a standard practice by veterinary staff for the treatment of malaria-induced anemia.

ELISA
Plates coated with either 3D7 or FVO AMA-1 (50 ng/well) were blocked with 5% BSA-PBS for 1 hr. Aotus sera were serially diluted four-fold starting from 1:1000 dilution and 75 μl of the dilution was incubated in the wells for 2 hrs at room temperature. The plates were washed thrice with PBS+0.05% Tween-20. Anti-A. nancymaae IgG heavy-plus-light chain peroxidase-labeled conjugate was diluted 1:10,000 in PBS-Tween and 50 μl/well was incubated for 1 hr at room temperature. Plates were washed and developed by the addition of 50 μl of 2,2’-azino-bis3-ethyl benzthiazoline-6-sulfonic acid (ABTS) peroxidase substrate system (KPL, Gaithersburg, MD). The optical density at 415 nm (OD415) was measured after 30 min using a microplate reader (Molecular Dynamics, Sunnyvale CA). The antibody endpoint titer was calculated as the serum dilution that produced an OD415 of 0.5 absorbance units in the ELISA assay using a 4 parameter curve fitting model in the Softmax software (Molecular Dynamics). The 0.5 OD415 fell in the linear part of the dilution curve.

Expression of Chimeric Proteins and Domain ELISA
AMA1 consists of 3 disulphide bonded domains, D1, D3 and D3 [22]. In order to map the immune response to the various domains of AMA1, we produced 5 chimeric proteins. These chimeric proteins display the individual P. falciparum 3D7 AMA1 D1, D2, D3, D1+2 and D2+3 on a P. berghei scaffold. The design, expression and purification of the chimeric proteins will be described elsewhere. The domain ELISA utilized the chimeric AMA1 proteins as coat antigens. Various chimeras at 50 ng/well were coated on the ELISA plates and the assay was done as above.

IFA
IFA slides were prepared from FVO and 3D7 asexual parasites grown to mature schizonts in vitro by depositing the infected erythrocytes into the wells and drawing the excess solution leaving a thin layer of cells that were allowed to air dry. Prepared slides were stored at ~80°C until thawed for use in the IFA analysis. Sera were diluted 1:32 with 0.01M PBS, pH 7.2, and two fold dilutions continuing to 1:65,536 were placed in the wells for 1 hour in a moist chamber. Slides were washed in PBS and a 1:100 dilution of FITC-labeled goat anti-Aotus monkey IgG was incubated in each well for another 1 hour in a moist chamber in the dark. After a second washing cycle the slides were dried, anti-fade mounting medium was applied and cover slip was mounted. Slides were then examined under a UV microscope. The dilution in the last well showing distinct fluorescence was taken as the IFA titer.
GIA
Sera were thawed at 37°C in a water bath and heat inactivated for 20 minutes at 56°C. Ring stages at 0.2% parasitemia and normal RBC at 2% hematocrit were seeded in a 96 well plate with a final culture volume of 40 μl. Sera was tested at a final concentration of 10% against the 3D7 strain of *P. falciparum* and 5% against the FVO strain in a one cycle GIA (FVO was inhibited by normal Aotus sera above 5% v/v). The plate was sealed in a gas filled plastic bag and incubated under static conditions for 40 hrs [23]. Ring stages of the parasite were stained by adding 5 μl of the dye to 500 μl of 0.25X SYBR green dye in pH 7.4 PBS containing 10 mM EDTA and 10 mM glucose [23,24]. Following 45 minute incubation in a shaking incubator maintained at 37°C, parasites were quantified by flow-cytometry (488/530 nm) using a BD FACScalibur (Franklin Lakes, NJ) gated on forward scatter for 40,000 RBC. Percent inhibition of invasion was calculated as, [1-(percent ring stage parasitemia in test well/percent ring stage parasitemia in pre-immune serum containing control well)].

Statistical Analysis
Data for the three FCH/4 challenged groups was evaluated by analysis of variance to discern if differences existed among the various groupings of data; multiple group comparisons were then made by Tukey’s posttest. Data of the 2 FVO challenged groups were compared by Mann–Whitney U test. Correlation between Log ELISA and cumulative day 11 parasitemia were established using the Spearman rank correlation. Plots were produced using Prism Graphpad (La Jolla, CA) or Microsoft Excel software (Redmond, WA).

Results

Sequence Differences between the Vaccine and Challenge Strain AMA1 Proteins
It was necessary to examine the potential protective effects of the human 3D7 vaccine against heterologous strains of *P. falciparum*, FCH/4 and FVO, because *P. falciparum* 3D7 parasite is not adapted to grow in Aotus monkeys. There are 12 amino acid differences between FCH/4 and 3D7 AMA1 as compared to 24 amino acid differences between FVO & 3D7 AMA1 (Figure 2, top panel). Since the 3D7 AMA1 vaccine consisted of amino acids 83–531 (grey cells in Figure 2), the sequence differences between the vaccine and the target strain within this sequence boundary were mapped to the crystal structure of AMA1 [25,26] (Figure 2, bottom panel). Eighteen of the 24 3D7-FVO amino acid differences localized to domain-1 as compared to 3 out of the 12 3D7-FCH/4 differences. Hence, the 3D7 and FCH/4 domain-1 and domain-2 sequences are very similar. Within domain-1 the

![Figure 2. The FCH/4 strain AMA1 is more homologous to 3D7 AMA1 as compared to FVO strain AMA1.](https://doi.org/10.1371/journal.pone.0008138.g002)
critical antigenic escape residues of AMA1 map to a group of polymorphisms within a three dimensional cluster termed C1, shown in Figure 2 as circled residues [27]. One of the 3D7-FCH/4 differences (residue 187) mapped to C1 as compared to 8 of the 3D7-FVO differences (residue numbers 187, 190, 196, 197, 200, 204, 206, 225). It was anticipated that the 3D7 vaccine was more likely to be effective against the C1-similar FCH/4 strain.

Reactogenicity and Immunogenicity

The 3D7 AMA1 vaccine formulated with either ISA or AS02A adjuvants was well tolerated by the non-human primates, with no indication of vaccine induced weight loss and only minor local reactions, primarily with ISA. Two of the monkeys died during the course of vaccination due to causes unrelated to the vaccine antigen; both deaths occurred in the PBS+ISA<sub>FVO</sub> control group. Monkey AI-3190 died suddenly 10 days post the first immunization with PBS.

Monkey AI-3205 died 3 days prior to challenge after minimal pathology with the exception of a mild chronic interstitial nephritis. These deaths were judged to be unrelated to the vaccine induced weight loss and only minor local reactions, primarily with ISA. Two of the monkeys died during the course of vaccination due to causes unrelated to the vaccine antigen; both deaths occurred in the PBS+ISA<sub>FVO</sub> control group. Monkey AI-3205 died 3 days prior to challenge after minimal pathology with the exception of a mild chronic interstitial nephritis. The mean titer of AMA1+ISA<sub>FCH/4</sub> group sera was 303,034 on 3D7 AMA1 coated plates and significantly lower, 69,696, against the heterologous FVO target parasite was not detectable (Table 1).

Overall these results indicated that the 3D7 AMA1 vaccine was inducing an efficient antibody response in Aotus monkeys, with higher levels of antibody detected with the ISA adjuvant, which resulted in efficient inhibition of the homologous 3D7 parasites. Levels of cross-reacting antibodies against FVO AMA1 protein were ~5x lower, which was insufficient for in vitro growth inhibition of the FVO parasite.

Analysis of Parasitemia Profiles

In order to determine if the 3D7 AMA1 vaccine had induced protection against FCH/4 and FVO parasite challenge, parasitemia profiles were examined for individual animals within the different immunization groups.

PBS+ISA<sub>FCH/4</sub> group. Inoculation of 50,000 P. falciparum FCH/4 strain parasitized RBC in the control PBS+ISA<sub>FCH/4</sub> group led to detectable parasitemia in all monkeys by day 5 post challenge. During the following days two different parasitemia profiles were observed. Three monkeys (AI-3162, 3168, 3200; solid lines in Figure 4) developed a rapidly rising "virulent" parasitemia that required drug treatment within 15 days of challenge. The peak parasitemia of AI-3162, AI-3168, AI-3200
were 280,000, 296,000 and 164,000 respectively. Three remaining monkeys (AI-3166, 3178, 3210; broken lines) had a rapidly growing but ‘self-limiting’ parasitemia profile (defined as not requiring drug treatment for high parasitemia), and eventually becoming subpatent by day 24, 20, and 23, respectively. AI-3166 and AI-3210 had brief recrudescent infections by days 50 and 43. Peak parasitemia in AI-3166, AI-3178 and AI-3210 were 78,300, 42,300 and 160,000 parasites per $\mu$L. The mean peak parasitemia of the 3 animals with virulent profile was 246,667/$\mu$L, and that of the 3 animals with a self-limiting profile was 93,533/$\mu$L.

AMA+ISA FCH/4 group. Monkey AI-3182 and AI-3226 had the virulent parasitemia profile that required treatment on day 12 and 13 and thus were classified as not protected. Monkey AI-3191 had a self-limiting parasitemia profile reaching 168,000 parasites per $\mu$L that was given anti-malarial treatment on day 19 due to severe anemia and, therefore, was also not considered protected. Monkey AI-3176, remained slide negative after the first challenge and was then re-challenged with additional 50,000 parasitized erythrocytes on day 16. AI-3176 remained smear-negative throughout the trial showing sterile immunity. Monkey AI-3179 also showed protection, it had a short period of low level parasitemia (~10 parasites/$\mu$L for 3 days) that self cured by day 8, following which this animal remained subpatent. Monkey AI-3181 was patent (240 parasites/$\mu$L) only on day 4 and then remained smear-negative. AI-3181 was also re-challenged on day 16 with 50,000 FCH/4 parasites, following which a parasitemic phase was observed starting at day 24, peaking at 108,000 parasites per $\mu$L on day 32, and then self-resolving by day 38. This monkey was protected against the first challenge and as indicated by its sub-patency and also against the re-challenge as indicated by a delay in patency (7 days vs. 3–4 days).

AMA+AS02A-FCH/4 group. All animals of the AMA+AS02A-FCH/4 group became smear positive between day 4 and day 6. Although no sterile protection was observed, the parasitemia profiles indicated that all 6 monkeys mirrored the self-limiting parasitemia profile (not requiring drug treatment for high parasitemia $\geq 200,000/\mu$L) as compared to 3 of 6 in the control group (Figure 4). Peak parasitemia ranged from 200,000 to 230,000/\mu$L.

### Table 1. Immunogenicity and efficacy data of individual animals.

| Group               | Animal ELISA (X1000) IFA GIA Parasites/$\mu$L (day 4–11) | Mean Parasites/\mu$L (day 4–11) |
|---------------------|----------------------------------------------------------|---------------------------------|
| PBS+ISA FCH/4       |                                                          |                                 |
| AI-3162             | 0.3 0.3 64 64 7% nd 52016 416130 280000                  |                                 |
| AI-3166             | 0.3 0.5 128 64 16% nd 23996 191970 59580                 |                                 |
| AI-3168             | 0 0.3 $<$32 32 27% nd 68358 546860 296000                |                                 |
| AI-3178             | 0.1 0.5 32 $<$32 0% nd 11468 91740 42300                 |                                 |
| AI-3200             | 0.3 0.3 32 32 0% nd 28413 227300 116000                 |                                 |
| AI-3210             | 0.3 0.2 $<$32 $<$32 $-$6% nd 55668 445350 160000        |                                 |
| AMA+AS02A FCH/4     |                                                          |                                 |
| AI-3057             | 70 36 4096 512 16% nd 37246 297970 164000               |                                 |
| AI-3172             | 78 17 8192 256 10% nd 12860 102880 72000                |                                 |
| AI-3177             | 261 133 8192 2048 57% nd 789 6310 4320                 |                                 |
| AI-3063             | 197 83 8192 4096 56% nd 9558 76460 44000                |                                 |
| AI-3195             | 45 25 2048 256 11% nd 7485 59880 15840                |                                 |
| AI-3211             | 48 30 8192 128 8% nd 1461 11700 7650                   |                                 |
| AMA+ISA FCH/4       |                                                          |                                 |
| AI-3176             | 2015 481 32768 8192 85% nd 0 0 0                        |                                 |
| AI-3179             | 912 352 16384 4096 84% nd 4 30 10                      |                                 |
| AI-3181             | 309 144 65536 4096 77% nd 30 240 240                   |                                 |
| AI-3182             | 163 116 8192 4096 59% nd 20498 163980 105000           |                                 |
| AI-3191             | 40 14 8192 128 22% nd 43531 348250 140000              |                                 |
| AI-3226             | 26 18 4096 1024 35% nd 26935 215490 84000              |                                 |
| PBS+ISA FVO**       |                                                          |                                 |
| AI-3054             | 0.3 0.7 64 64 13% 4% 107451 859610 64000                |                                 |
| AI-3163             | 0.8 0.7 256 256 $-$11% 0% 11843 94740 87000           |                                 |
| AI-3185             | 0.3 0.4 128 128 13% 5% 60233 481860 288000            |                                 |
| AI-3199             | 0.3 0.3 32 32 $-$2% $-$1% 94416 755330 52000            |                                 |
| AMA+ISA FVO         |                                                          |                                 |
| AI-3055             | 733 129 16384 2048 63% 4% 162510 1300080 104000        |                                 |
| AI-3173             | 140 44 8192 2048 24% $-$2% 38165 228990 208000         |                                 |
| AI-3174             | 557 134 8192 1024 67% 15% 17030 136240 56000           |                                 |
| AI-3193             | 232 52 8192 2048 48% 2% 54651 437210 320000           |                                 |
| AI-3203             | 57 29 8192 4096 6% 0% 63575 508600 400000             |                                 |
| AI-3209             | 98 31 2048 2048 8% 3% 55638 445110 348000             |                                 |

Vaccine and challenge groups, animal ID, ELISA endpoint titer against 3D7 or FVO AMA1 coated plates, IFA titer against 3D7 and FVO schizonts, GIA activity against P. falciparum 3D7 or FVO target parasite and parasite burden (mean, peak and cumulative counts) between days 4 and 11 post challenge are shown. ** Two animals in the PBS+ISA FVO group died due to unrelated causes during the vaccination phase. GIA was not done (nd). The ELISA titer values are 1000X.

doi:10.1371/journal.pone.0008138.t001
parasitemia profile received drug treatment on day 11 and day 20, respectively, due to severe anemia. Thus, this group perhaps showed a degree of partial protection. However the mean peak parasitemia of the six self-limiting parasitemia profile monkeys in the AMA+AS02A-FCH/4 group (130,773/µL), was not different from the 3 control group animals (93,533/µL) that had a self-limiting profile (2 tailed t-test, p = 0.6).

PBS+ISAFVO group: There were only 4 animals in the control PBS+ISAFVO group at the time of challenge due to the death of 2 monkeys during the vaccination phase. Infection induced by inoculating 10,000 FVO strain parasitized RBC led to a rapidly rising virulent parasitemia profile in all 4 control monkeys with anti-malarial drug cure given between day 11 and 13 (Figure 4).

AMA+ISAFVO group. All of the 6 animals had a virulent parasitemia profile comparable to the PBS+ISAFVO control group. Five monkeys had to be treated for high parasitemia on day 9 or 11. One other monkey (AI-3174) peaked at 112,000 parasites/µL and on day 19 was treated with MQ and quinine for infection and

Figure 4. Parasitemia profiles of FCH/4 and FVO challenged groups. Daily parasitemia of animals plotted against days-post-challenge (days). Solid lines represent a virulent parasitemia profile that required drug treatment for high parasitemia (>200,000/µL) within 15 days of challenge. Broken lines represent a slower progressing and self-limiting infection profile. The challenge strains are indicated in parentheses (FCH/4 or FVO). Two monkeys in the AMA+ISAFCH/4 group (AI3181, AI-3176) were re-challenged on day 16.
doi:10.1371/journal.pone.0008138.g004

Infection induced by inoculating 10,000 FVO strain parasitized RBC led to a rapidly rising virulent parasitemia profile in all 4 control monkeys with anti-malarial drug cure given between day 11 and 13 (Figure 4).

AMA+ISAFVO group. All of the 6 animals had a virulent parasitemia profile comparable to the PBS+ISAFVO control group. Five monkeys had to be treated for high parasitemia on day 9 or 11. One other monkey (AI-3174) peaked at 112,000 parasites/µL and on day 19 was treated with MQ and quinine for infection and
severe anemia. No protection was observed against heterologous FVO strain challenge (Figure 4).

Parasite Burden and Correlates of Protection

Mean, peak and cumulative parasite levels were determined for group-wise comparisons. The first monkey in the FCH/4 challenged groups became parasitemic on day 4 and was drug treated on day 11, hence the relative parasite burden of the FCH/4 challenged groups was compared between days 4–11 (Figure 5 and Table 1). There was no clear difference between the parasite burden of the AMA1+V4O and the PBS+V4O groups were compared by Mann-Whitney U test (not plotted). No difference in the parasite burden was observed between the vaccine and the control group following FVO parasite challenge.

A plot of the mean cumulative parasitemia revealed further differences between the FCH/4 challenged groups (Figure 6, left panel). The rate of parasite growth indicated by the steepness of the cumulative parasitemia curve indicated that AMA1 vaccine had slowed the rate of FCH/4 multiplication in both the adjuvant groups as compared to the PBS control vaccine. The mean cumulative parasitemia on day 11, for the PBS-AS02A+FCH/4 group (319,892) was higher than the AMA1+V4O+FCH/4 group (121,332; Mann-Whitney U test p = 0.06), and the AMA1+V4O controls group (92,533, p = 0.02). Among the 2 FVO strain challenged groups, there was no difference in the growth rates between the vaccine and control group following FVO parasite challenge.

In this study, 18 animals in 3 groups were challenged with FCH/4 strain. Three monkeys in the AMA1+V4O+FCH/4 group were protected; AI-3176 and AI-3179 had greatly reduced or no parasite burden and AI-3181 had a delayed parasitic phase. The GIA activity of serum from these 18 monkeys was plotted against the log ELISA titer (Figure 7, left panel). Sera from these three monkeys had >70% GIA activity, >300,000 ELISA titer and IFA titer >8192 (Table 1). There was also a negative correlation between the cumulative parasitemia on day 11 and the log ELISA endpoint titer (Figure 7, right panel). Spearman rank test confirmed the statistical significance of this correlation (rho factor r = -0.780 and p = 0.000134).

Domain-Wise Mapping of Antibody Responses

To determine the differences in specificity of antibodies induced by the two adjuvants, and to explore if a particular domain-specific pattern correlated with protection, chimeric AMA1 proteins were used to determine the ELISA end-point titer against 3D7 AMA1 domains-1, 2, 3, 1+2 and 2+3 (termed D1, D2, D3, D1+2, D2+3 respectively). The mean end-point titer of 12 AMA1 vaccinated monkeys against the protein chimeras D1, D2, D3, D1+2 and D2+3 proteins respectively. The mean end-point titer of 12 AMA1 vaccinated monkeys against the protein chimeras D1, D2, D3, D1+2 and D2+3 were 45053, 48971, 14708, 103803 and 56107 respectively. Although, the contribution of antibodies that cross-react with the P. berghei AMA1 in this mapping analysis cannot be ruled out, the mean endpoint titer of the 12 monkeys against the recombinant scaffold protein P. berghei AMA1 was significantly lower, 3202, than the chimeric proteins that display PIAMA1 epitopes. To normalize the individual animal titers, the domain-specific end-point titer was expressed as a percentage of the titer against the full-length AMA1 protein. The mean domain-specific titer of AMA1+AS02A+FCH/4 and AMA1+V4O+FCH/4 groups was plotted in Figure 8. Analysis of variance, followed by Tukey’s postest showed no difference in domain specificity of antibodies induced by AS02A vs. V4O adjuvant. Among the single domains, the reactivity pattern was D1=D2=D3 and among the double domains, reactivity pattern was D1+2=D2+3. Proportion of antibodies against the D1+2 was highest between the domains and was statistically indistinguishable from the titer against the full-length antigen for both AMA1+V4O and AMA1+AS02A groups (Tukeys multiple comparison, p>0.05), indicating that the majority of the antibodies that bind to the full-length antigen recognize epitopes formed by residues present on domains 1 and 2. Figure 9 shows the end-point titers of all 12 AMA1 vaccinated and FCH/4 challenged monkeys. Individual serum titers showed that protection did not correlate with a unique domain specific antibody induction pattern, instead the titers in the AMA1+V4O group were generally lower against all domains and the protected monkeys (AI-3176, AI-3179 and AI-3181) had D1+2 titers exceeding 100,000 (Figure 9), suggesting that magnitude of antibody response to the full-length AMA1 and domains+2 are a critical correlate of AMA1 based protection.

Discussion

The 3D7 strain of Plasmodium falciparum grows vigorously in vitro and was used for the first genome sequencing of a malaria parasite [29]. This strain of P. falciparum also produces gametocytes and its sensitivity to chloroquine has made it an excellent choice as a
challenge strain for human Phase 2a vaccine trials [30]. Despite numerous attempts made at the CDC Atlanta by Dr. William Collins and others, the 3D7 parasite could not be adapted to grow in the New World monkey models (personal communication). Hence, in order to test the efficacy of a 3D7 strain based AMA1 vaccine, we utilized two heterologous strains FCH/4 and FVO. The FVO strain is highly virulent in Aotus nancymae, whereas, the FCH/4 strain is less well adapted. In this study, a dose of 50,000 FCH/4 strain parasites produced virulent infection requiring drug treatment in 3 of 6 animals in the control group, while the remaining 3 animals self-cured after developing high parasitemia (Figure 4). In comparison, only 10,000 parasites of the FVO strain were sufficient to produce a rapidly rising virulent infection in 4 of 4 control monkeys, all of which required drug treatment (Figure 4). Positive efficacy of the AMA+ISA vaccine against a FCH/4 strain challenge was observed where protection, as measured by a reduced parasite burden, was 50% and as measured by sterile protection, was 16% (Figure 4, 5 and 6). The animals in the AMA+AS02A group had a reduced rate of parasitemia increase that did eventually reach a high mean peak parasitemia that was surprisingly higher than the parasitemia of the control group monkeys with a self-limiting profile. None of the animals in the AMA+AS02A group needed treatment for the hyper-parasitemia, although two were treated for severe anemia. ELISA and IFA titers showed that anti-3D7 AMA1 antibodies had lower recognition of the FVO strain AMA1, and, this was associated with 0% efficacy of the AMA+ISA vaccine against the more virulent FVO strain.

Although FCH/4 is less virulent than the FVO strain, it was chosen as one of the two challenge strains because it was the nearest in amino acid sequence of AMA1 to 3D7 among a group of monkey adapted P. falciparum strains available for challenge.

Figure 6. 3D7 AMA1 vaccination slowed growth rate of FCH/4 but not FVO strain. Group-wise mean cumulative parasitemia of the FCH/4 (left panel) and FVO (right) challenged animals plotted against days post challenge. Solid line, PBS control group; broken line, AMA+ISA; dotted line, AMA+AS02A. doi:10.1371/journal.pone.0008138.g006

Figure 7. ELISA titers positively correlate GIA activity and negatively correlate parasitemia. Left panel shows GIA activity of the FCH/4 challenged animals plotted against log ELISA titer. Group symbols: PBS+ISA (triangle), AMA+ISA (cross) and AMA+AS02A (square). The three monkeys that were protected in the study had GIA activity of >70% and ELISA titer of >300,000, cut-off indicated by grey lines. Right panel shows the correlation between log ELISA endpoint titer and the cumulative day 11 parasitemia for the 18 FCH/4 challenged animals. doi:10.1371/journal.pone.0008138.g007
infections. The structural distribution of the amino acid differences between 3D7 and FCH/4 versus 3D7 and FVO was analyzed to rationalize the observed pattern of heterologous protection. We have previously shown that the antigenic escape residues of 3D7 AMA1 reside within a small three dimensional cluster called C1 [27] (Figure 2). This cluster contains the most polymorphic sites (residues 187, 190, 196, 197, 200, 204, 206, 225) of AMA1. Interestingly, only one amino acid difference between 3D7-FCH/4 mapped to the C1 cluster (Figure 2), as compared to 8 differences between 3D7-FVO. Indeed, the majority of the differences between 3D7 and FCH/4 in AMA1 mapped to domain-3 (residues 448, 496, 503, 512). Published cross-strain inhibition data using anti-3D7 antibodies against P. falciparum D10 strain target parasites has shown that three out of the four 3D7-FCH/4 domain-3 amino acid differences confer no escape advantage to the D10 strain parasite in a cross-strain GIA against anti-3D7 AMA1 [31]. The FCH/4 strain was, therefore, an appropriate choice to study the protective efficacy of 3D7 strain AMA1 vaccine formulation.

The most likely cause of vaccine failure in the FVO challenged animals was therefore antigenic escape from strain-specific 3D7 AMA1 antibodies. Alternatively, there may be differences in the relative susceptibility of FCH/4 and FVO strains to invasion inhibitory AMA1 antibodies. We have shown previously that affinity purified antibody required for 50% invasion inhibition was lower for the 3D7 strain parasite, as compared to the FVO strain [27]. This suggested that FVO parasite may be inherently more resistant to inhibition by anti-AMA1. Most importantly future AMA1 vaccines need to be evaluated for their ability to inhibit multiple strains of the parasite as well as some primary isolates that may use multiple invasion pathways.

Three out of the 12 AMA1 vaccinated monkeys (compared to 0 of 6 adjuvant control monkeys) were strongly protected against a relatively homologous, yet weak, challenge strain FCH/4. The protected monkeys had the highest GIA activity, high IFA titer and highest ELISA titer against full-length and domains1+2 of AMA1. There was a negative correlation between mean parasite count and ELISA titer and protection correlated with a threshold antibody titer, which was achieved in some monkeys of the ISA720 group, but not in the AS02A group. An AMA+AS02A formulation failed to induce sterilizing immunity in humans in a Phase 1/2a trial [16], although it reduced the parasite growth rate, as was observed for AS02A formulation group in this Aotus study. It is difficult to compare the absolute antibody titers between species, but GIA activity of the sera can be more accurately compared. In the Phase1/2a trial, the mean GIA activity measured using 20% v/v serum concentration against the 3D7 strain parasite was 30% (range 10–40%) [16], which is concordant with a dose escalation Phase 1 trial where the AMA+AS02A vaccine induced GIA activity in the 30–40% range, also at 20% serum concentration [14]. In a recently published human Phase 1 trial with FVO AMA1 vaccine, adjuvanted with IS720 and AS02, the mean GIA activity was in the 20–30% range at 10 mg/ml IgG [32], for both adjuvant groups. The 10 mg/ml concentration is close to the physiological concentration of IgG in the serum, and our data suggests that significantly higher level of invasion inhibition (>70% activity at one tenth the equivalent serum concentration, advantage to the D10 strain parasite in a cross-strain GIA against anti-3D7 AMA1 [31]. The FCH/4 strain was, therefore, an appropriate choice to study the protective efficacy of 3D7 strain AMA1 vaccine formulation.

The most likely cause of vaccine failure in the FVO challenged animals was therefore antigenic escape from strain-specific 3D7 AMA1 antibodies. Alternatively, there may be differences in the relative susceptibility of FCH/4 and FVO strains to invasion inhibitory AMA1 antibodies. We have shown previously that affinity purified antibody required for 50% invasion inhibition was lower for the 3D7 strain parasite, as compared to the FVO strain [27]. This suggested that FVO parasite may be inherently more resistant to inhibition by anti-AMA1. Most importantly future AMA1 vaccines need to be evaluated for their ability to inhibit multiple strains of the parasite as well as some primary isolates that may use multiple invasion pathways.

Three out of the 12 AMA1 vaccinated monkeys (compared to 0 of 6 adjuvant control monkeys) were strongly protected against a relatively homologous, yet weak, challenge strain FCH/4. The protected monkeys had the highest GIA activity, high IFA titer and highest ELISA titer against full-length and domains1+2 of AMA1. There was a negative correlation between mean parasite count and ELISA titer and protection correlated with a threshold antibody titer, which was achieved in some monkeys of the ISA720 group, but not in the AS02A group. An AMA+AS02A formulation failed to induce sterilizing immunity in humans in a Phase 1/2a trial [16], although it reduced the parasite growth rate, as was observed for AS02A formulation group in this Aotus study. It is difficult to compare the absolute antibody titers between species, but GIA activity of the sera can be more accurately compared. In the Phase1/2a trial, the mean GIA activity measured using 20% v/v serum concentration against the 3D7 strain parasite was 30% (range 10–40%) [16], which is concordant with a dose escalation Phase 1 trial where the AMA+AS02A vaccine induced GIA activity in the 30–40% range, also at 20% serum concentration [14]. In a recently published human Phase 1 trial with FVO AMA1 vaccine, adjuvanted with IS720 and AS02, the mean GIA activity was in the 20–30% range at 10 mg/ml IgG [32], for both adjuvant groups. The 10 mg/ml concentration is close to the physiological concentration of IgG in the serum, and our data suggests that significantly higher level of invasion inhibition (>70% activity at one tenth the equivalent serum concentration,
10% v/v) is required to confer protection. The sera from the Phase 1/2a trial [16] also failed to cause cross-strain inhibition of the FVO parasite, which was also observed in our non-human primate study reported here.

Viral neutralization titer is generally defined as the serum dilution that neutralizes 50% of virus. It is easier and more accurate to titrate out antibodies to a 50% end-point than to measure higher levels of neutralization or inhibition directly. Harmonization of assay protocols for several virus diseases has allowed comparison of vaccine efficacy between trials. A 50% plaque reduction neutralization titer of >120 (1:120 serum dilution) correlates with protection against measles [33] and a 50% neutralization titer of >23 against the influenza virus also correlates protection [34]. Our data suggests that 70% inhibition (neutralization) at 1:10 serum dilution is adequate to protect against a malaria challenge in Aotus monkeys. Limitations in availability of Aotus sera did not allow us to use higher concentrations of serum antibodies. We expect that antibodies in undiluted sera would have greater than 90% inhibition of FCH/4 in GIA, although we cannot rule out other immune mechanisms.

This result is not surprising because the growth-rate of *P. falciparum* parasites in *vivo* is between 6–15 fold per cycle, and a high level of GIA activity is needed to induce solid protection. Thus far no human-use vaccine formulation has met this GIA activity. If viral neutralization titers are an indication, malaria vaccine formulations need to generate significantly higher titers to induce sterile protection. This may be further complicated by other anti-malaria antibodies, prevalent in endemic populations, that block the anti-AMA1 mediated invasion inhibition [35]. Future Aotus trials using Montanide formulations of AMA1 can provide an opportunity to confirm the current findings and to establish a cut-off ELISA titer/antibody concentration that human-use formulations must achieve, prior to entering advanced human trials.

AMA1 antibodies also need to be capable of inhibiting invasion across a broad range of parasite strains. A Phase 2b study using a bi-allelic 3D7+FVO AMA1 vaccine in 300 Malian children, showed no impact of vaccination on the frequency of parasitemic episodes. The 3D7 based AMA1 vaccine used in our manuscript has been evaluated in a series of clinical trials, culminating in a Phase 2b trial in Mali, Africa, an area of significant *P. falciparum* genetic diversity [Chris Plowe, University of Maryland, personal communication]. If the current generation of 3D7 and FVO AMA1 based vaccines [30], fail to reduce parasite burden in children, structural vaccinology [27] and population biology [37] approaches will be needed to engineer a second generation antigen, that induces higher titer of cross-reactive inhibitory antibodies. Aotus monkey trials can serve as an important down selection-criteria to make critical go-no-go decisions, prior to testing the next generation of AMA1 based vaccines in humans. Novel formulation and delivery platform selection studies can benefit from a threshold GIA activity reported here, as a correlate of AMA1 based protection in the Aotus model.

**Acknowledgments**

We would like to thank Craig Morrisey, Walter Reed Army Institute of Research, for statistical analysis and Erika Lin Chao for technical support. We would also like to thank J. Kathleen Moch for growing the parasites used in the GIA. We thank GlaxoSmithKline Biologicals for providing the AS02 Adjuvant System and Yannick Vanloubbeeck, Marie-Claude Dubois and Joe Cohen, for reviewing and commenting on the manuscript.

**Author Contributions**

Conceived and designed the experiments: SD LS CD DGH DL WEC JWB. Performed the experiments: SD JSS KKG JDH JK AHB WEC JWB. Analyzed the data: SD WEC JWB. Contributed reagents/materials/analysis tools: SD WEC JWB. Wrote the paper: SD WEC JWB.

**References**

1. Bejon P, Lusingu J, Olotu A, Leach A, Lievens M, et al. (2008) Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. N Engl J Med 359: 2521–2532.

2. Heppner DG, Jr., Kester KE, Ockenhouse CF, Tornieporth N, Ofori O, et al. (2003) Towars a RTS,S-based, multi-stage, multi-antigen vaccine against *Plasmodium falciparum* malaria: progress at the Walter Reed Army Institute of Research. Vaccine 23: 2249–2250.

3. Peterson MG, Marshall VM, Smythe JA, Crevedter PE, LeW A, et al. (1989) Integral membrane protein located in the apical complex of *Plasmodium falciparum*. Mol Cell Biol 9: 3131–3134.

4. Bannister LH, Hopkins J, Dhuzerwi AR, Margos G, Williams G, et al. (2003) *Plasmodium falciparum* apical membrane antigen 1 (AMA-1) is translocated within micronemes along subpellicular microtubules during merozoite development. J Cell Sci 116: 3825–3834.

5. Triglia T, Healer J, Caruana SR, Hodder AN, Anders RF, et al. (2000) Apical membrane antigen 1 plays a central role in erythrocyte invasion by *Plasmodium* species. Mol Microbiol 36: 706–718.

6. Kennedy MC, Wang J, Zhang Y, Miles AP, Chitas F, et al. (2002) In vitro studies with recombinant *Plasmodium falciparum* apical membrane antigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic response. Infect Immun 70: 6948–6960.

7. Silvio O, Franetzki JF, Charrin S, Mueller MS, Siau A, et al. (2004) A role for apical membrane antigen 1 during invasion of hepatocytes by *Plasmodium falciparum* sporozoites. J Biol Chem 279: 49497–49499.

8. Deans JA, Knight AM, Ju PW, Waters AP, Cohen S, et al. (1998) Vaccination trials in rhesus monkeys with a minor, invariant, *Plasmodium knowlesi* 66 kD merozoite antigen. Parasite Immunol 10: 535–552.

9. Collins WE, Pye D, Crevedter PE, Vanderberg KL, Galland GD, et al. (1994) Protective immunity induced in squirrel monkeys with recombinant apical membrane antigen-1 of *Plasmodium falciparum*. J Infect Dis 169: 711–719.

10. Kocken CH, Dubbeld MA, Van Der Wel A, Pronk JT, Waters AP, et al. (1999) High-level expression of *Plasmodium* vivax apical membrane antigen 1 (AMA-1) in *Plasmodium falciparum* parasites in *vivo*. J Infect Dis 180: 1162–1169.

11. Crewther PE, Matthew ML, Flegg RH, Anders RF (1996) Protective immune responses to apical membrane antigen 1 of *Plasmodium chabaudi* involve recognition of strain-specific epitopes. Infect Immun 64: 3310–3317.

12. Lynch MM, Cernetchi-Ott A, Weidanz WP, Burns JM, Jr. (2009) Prediction of merozoite surface protein 1 and apical membrane antigen 1 vaccine efficacy against *Plasmodium chabaudi* malaria based on prechallenge antibody responses. Clin Vaccine Immunol 16: 293–302.

13. Stowers AW, Kennedy MC, Keegan BP, Saul A, Long CA, et al. (2002) Vaccination of monkeys with recombinant *Plasmodium falciparum* apical membrane antigen 1 confers protection against blood-stage malaria. Infect Immun 70: 6961–6967.

14. Polhemus ME, Magill AJ, Cummings JF, Kester KE, Ockenhouse CF, et al. (2007) Phase 1 dose escalation safety and immunogenicity trial of *Plasmodium falciparum* apical membrane protein 1 (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naive adults at the Walter Reed Army Institute of Research. Vaccine 25: 4203–4212.

15. Thera MA, Dounmbo OK, Coulibaly D, Diallo DA, Kone AK, et al. (2008) Safety and immunogenicity of an AMA1 malaria vaccine in Malian adults: results of a phase 1 randomized controlled trial. PLoS One 3: e1465.

16. Spring MD, Cummings JF, Ockenhouse CF, Dutta S, Reidier R, et al. (2009) Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adult system AS01B or AS02A. PLoS One 4: e5254.

17. Kaneko O, Soubes SC, Miller LH (1999) High-level expression of *Plasmodium falciparum* apical membrane antigen-1 (AMA-1) in *Plasmodium falciparum* parasites in *vivo*. J Infect Dis 179: 116–119.

18. Faundez T, Chalvet W (1998) Variant- and strain-specific immunity in *Saimiri sciureus* infected with *Plasmodium falciparum*. Am J Trop Med Hyg 58: 225–231.

19. Collins WE, Galland GG, Sullivan JS, Moisin CL (1994) Selection of different strains of *Plasmodium falciparum* for testing blood-stage vaccines in *Aotus nancymai* monkeys. Am J Trop Med Hyg 51: 224–252.
20. Dutta S, Lalitha PV, Ware LA, Barbosa A, Moch JK, et al. (2002) Purification, characterization, and immunogenicity of the refolded ectodomain of the Plasmodium falciparum apical membrane antigen 1 expressed in Escherichia coli. Infect Immun 70: 3101–3110.

21. Thomas AW, Trope JF, Rogier C, Goncalves A, Rosario VE, et al. (1994) High prevalence of natural antibodies against Plasmodium falciparum 83-kilodalton apical membrane antigen (PF83/AMA-1) as detected by capture-enzyme-linked immunosorbent assay using full-length baculovirus recombinant PF83/AMA-1. Am J Trop Med Hyg 51: 730–740.

22. Hodder AN, Crewther PE, Matthew MI, Reid GE, Moritz RL, et al. (1996) The disulfide bond structure of Plasmodium apical membrane antigen-1. J Biol Chem 271: 29446–29452.

23. Haynes JD, Moch JK, Smoot DS (2002) Erythrocytic malaria growth or invasion inhibition assays with emphasis on suspension culture GIA. Methods Mol Med 72: 533–554.

24. Izumiya S, Omura M, Takasaki T, Ohnme H, Asahi H (2009) Plasmodium falciparum: development and validation of a measure of intracellular growth using SYBR Green I in a flow cytometer. Exp Parasitol 121: 144–150.

25. Bai T, Becker M, Gupta A, Strike P, Murphy VJ, et al. (2005) Structure of AMA1 from Plasmodium falciparum reveals a clustering of polymorphisms that surround a conserved hydrophobic pocket. Proc Natl Acad Sci U S A 102: 12736–12741.

26. Pizarro JC, Vulliez-Le Normand B, Chesne-Seck ML, Collins CR, Withers-Martinez C, et al. (2003) Crystal structure of the malaria vaccine candidate apical membrane antigen 1. Science 308: 408–411.

27. Dutta S, Lee SY, Batchelor AH, Lanar DE (2007) Structural basis of antigenic escape of a malaria vaccine candidate. Proc Natl Acad Sci U S A 104: 12488–12493.

28. Nagatake T, Broderson JR, Tegoshi T, Collins WE, Aikawa M (1992) Renal pathology in owl monkeys vaccinated with Plasmodium falciparum asexual blood-stage synthetic peptide antigens. Am J Trop Med Hyg 47: 614–620.

29. Hall N, Pain A, Berrian M, Churcher G, Harris B, et al. (2002) Sequence of Plasmodium falciparum chromosomes 1, 3-9 and 13. Nature 419: 527–531.

30. Epstein JE, Rao S, Williams F, Freilich D, Lake T, et al. (2007) Safety and clinical outcome of experimental challenge of human volunteers with Plasmodium falciparum-infected mosquitoes: an update. J Infect Dis 196: 145–154.

31. Hodder AN, Crewther PE, Anders RF (2001) Specificity of the protective antibody response to apical membrane antigen 1. Infect Immun 69: 3286–3294.

32. Roestenberg M, Remarque E, de Jonge E, Hermens R, Blythman H, et al. (2000) Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Alhydrogel, Montanide ISA 720 or AS02. PLoS One 3: e3960.

33. Chen RT, Markowitz LE, Albrecht P, Stewart JA, Mofenson LM, et al. (1990) Measles antibody: reevaluation of protective titers. J Infect Dis 162: 1036–1042.

34. Lehtoranta L, Villberg A, Santanen R, Ziegler T (2009) A novel, colorimetric neutralization assay for measuring antibodies to influenza viruses. J Virol Methods 159: 271–276.

35. Miura K, Zhou H, Moretz SE, Diouf A, Thera MA, et al. (2008) Comparison of biological activity of human anti-apical membrane antigen-1 antibodies induced by natural infection and vaccination. J Immunol 181: 8776–8783.

36. Dicko A, Sagara I, Ellis RD, Miura K, Guindo O, et al. (2008) Phase 1 study of a combination AMA1 blood stage malaria vaccine in Malian children. PLoS One 3: e1563.

37. Duan J, Mu J, Thera MA, Joy D, Kosakovsky Pond SL, et al. (2008) Population structure of the genes encoding the polymorphic Plasmodium falciparum apical membrane antigen 1: implications for vaccine design. Proc Natl Acad Sci U S A 105: 7857–7862.